Vimarsana
Biggest News Aggregation in the World

David Shao News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David Shao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Shao Today - Breaking & Trending Today

YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript - Vimarsana News

YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript

YS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcript April 19, 2024 YS Biopharma Co., Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by and welcome to YS Biopharma’s Earnings Call […]

Source: yahoo.com
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility - Vimarsana News

YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company

YS Biopharma Announces US$40 Million Private Placement Financing - Vimarsana News

YS Biopharma Announces US$40 Million Private Placement Financing

GAITHERSBURG, Md., Feb. 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. along with its subsidiaries , a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and...

YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 - Vimarsana News

YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024

/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical...

YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 - Vimarsana News

YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024

GAITHERSBURG, Md., Jan. 23, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the